Richard Buus
Richard Buus
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Verified email at icr.ac.uk - Homepage
Title
Cited by
Cited by
Year
Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy
R Buus, I Sestak, R Kronenwett, C Denkert, P Dubsky, K Krappmann, ...
Journal of the National Cancer Institute 108 (11), djw149, 2016
1672016
Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial
I Sestak, R Buus, J Cuzick, P Dubsky, R Kronenwett, C Denkert, S Ferree, ...
JAMA oncology 4 (4), 545-553, 2018
1352018
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
F Brasó-Maristany, S Filosto, S Catchpole, R Marlow, J Quist, ...
Nature medicine 22 (11), 1303-1313, 2016
1192016
Key role of phosphoinositide 3-kinase class IB in pancreatic cancer
CE Edling, F Selvaggi, R Buus, T Maffucci, P Di Sebastiano, H Friess, ...
Clinical cancer research 16 (20), 4928-4937, 2010
992010
Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells
R Buus, M Faronato, DE Hammond, S Urbé, MJ Clague
Current Biology 19 (17), 1463-1466, 2009
512009
Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials
M Falasca, F Selvaggi, R Buus, S Sulpizio, C E Edling
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2011
462011
Regulation of ErbB2 receptor status by the proteasomal DUB POH1
H Liu, R Buus, MJ Clague, S Urbé
PloS one 4 (5), e5544, 2009
462009
Changes in expression of genes representing key biologic processes after neoadjuvant chemotherapy in breast cancer, and prognostic implications in residual disease
M Klintman, R Buus, MCU Cheang, A Sheri, IE Smith, M Dowsett
Clinical cancer research 22 (10), 2405-2416, 2016
352016
Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer
M Dowsett, I Sestak, R Buus, E Lopez-Knowles, E Mallon, A Howell, ...
Clinical Cancer Research 21 (12), 2763-2770, 2015
302015
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
I Sestak, M Martín, P Dubsky, R Kronenwett, F Rojo, J Cuzick, M Filipits, ...
Breast cancer research and treatment 176 (2), 377-386, 2019
192019
Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC
I Sestak, R Buus, J Cuzick, P Dubsky, R Kronenwett, S Ferree, D Sgroi, ...
Cancer Research 77 (4 Supplement), S6-05-S6-05, 2017
192017
Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression
A Chikh, R Ferro, JJ Abbott, R Pińeiro, R Buus, M Iezzi, F Ricci, ...
Oncotarget 7 (14), 18325, 2016
132016
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
E Lopez-Knowles, A Pearson, G Schuster, P Gellert, R Ribas, B Yeo, ...
British journal of cancer 120 (2), 247-255, 2019
102019
Comprehensive comparison of prognostic signatures for breast cancer recurrence in TransATAC
I Sestak, R Buus, J Cuzick, P Dudsky, R Kronenwett, S Ferree, D Sgroi, ...
San Antonio Breast Cancer Symposium, S6-S05, 2016
102016
Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms
C Fyffe, R Buus, M Falasca
Current pharmaceutical design 19 (4), 680-686, 2013
92013
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
R Buus, B Yeo, AR Brentnall, M Klintman, MCU Cheang, K Khabra, ...
Breast Cancer Research 20 (1), 103, 2018
72018
Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
MF Leal, BP Haynes, E Schuster, B Yeo, M Afentakis, L Zabaglo, ...
Clinical Cancer Research 25 (24), 7485-7496, 2019
62019
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer
BP Haynes, O Ginsburg, Q Gao, E Folkerd, M Afentakis, R Buus, PT Han, ...
NPJ breast cancer 5 (1), 1-11, 2019
62019
Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study
K Lawler, E Papouli, C Naceur-Lombardelli, A Mera, K Ougham, A Tutt, ...
Breast Cancer Research 19 (1), 113, 2017
52017
Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
F Braso-Maristany, S Filosto, S Catchpole, R Marlow, J Quist, ...
Nature medicine 23 (4), 526, 2017
52017
The system can't perform the operation now. Try again later.
Articles 1–20